MarketReview reviews Medicare Part D prescription drug coverage differently from products where one national price or benefit package can represent the entire offering. A Part D company may operate one consumer-facing portfolio under a CMS prescription drug contract while the exact plans available to beneficiaries vary by region, formulary, pharmacy network, cost sharing and other plan-specific terms.
Our reviews are designed to evaluate the Part D portfolio without pretending that one regional plan represents every version sold under the same brand. We combine official Medicare information, CMS contract data, current carrier materials and exact-plan evidence where it helps explain how the portfolio works. The result is an editorial assessment of the portfolio for a specific plan year, not a prediction of what every beneficiary will pay.
What exactly receives a MarketReview Rating
For standalone Medicare Part D coverage, the rating subject is the consumer-facing prescription drug plan portfolio associated with a CMS PDP contract for the stated plan year.
That distinction is deliberate. A company may market several plan families under one Part D portfolio, and each family can appear through different regional plan benefit packages. Those exact plans may have different premiums, deductibles, formularies, pharmacy arrangements and cost sharing even though they belong to the same broader portfolio.
MarketReview does not assign a separate editorial rating to every regional PBP simply because CMS records them separately. Doing so could imply a level of independent evaluation that the evidence does not support and would make the rating difficult to interpret across regions.
Instead, one authoritative MarketReview Rating applies to the defined portfolio subject and plan year. Exact-plan information can inform that assessment, but an individual regional specimen does not become the rating subject by itself.
We begin with the evidence that defines the product
Part D reviews are research-based. Unless a review explicitly states otherwise, we do not claim to have enrolled in the plan, filled prescriptions through it, called member services as an enrollee or personally experienced the claims process.
Our strongest evidence generally comes from CMS and Medicare materials, official contract and quality data, formularies, Evidence of Coverage documents, Summary of Benefits materials, pharmacy directories, utilization-management documents and other plan or sponsor disclosures. Current carrier websites and member resources can provide additional information about plan families, prescription tools, mail order and how the company presents its coverage to consumers.
Not every source answers the same question. CMS data may establish contract identity or quality information. A formulary can establish whether a drug is listed and whether restrictions apply. A pharmacy directory can show network participation. A carrier marketing page may explain how a plan family is positioned, but marketing language is not treated as independent evidence that the plan is broadly cheaper or better.
When information is regional or tied to one exact plan, we keep that limitation attached to the evidence rather than generalizing it across the portfolio.
Drug coverage is more than the length of a formulary
The central function of Part D coverage is paying for prescription drugs, so formulary design receives substantial attention in our reviews. We are interested not only in whether a company maintains a broad drug list, but in how the coverage is structured and what could make access more difficult or expensive for a member.
That can include the number and purpose of drug tiers, treatment of common generic and brand medications, specialty-drug placement and the use of prior authorization, step therapy or quantity limits. These restrictions are legitimate features of Medicare drug-plan design, but they can materially affect how usable coverage is for someone taking a particular medication.
We do not build a rating by counting covered drugs and declaring the longest formulary the winner. Two formularies can cover the same medication while producing very different cost sharing or access requirements. A portfolio with several plan families may also use different formularies or benefit structures across those families.
The review therefore looks for meaningful patterns while making clear that beneficiaries still need to check their own prescriptions against the exact plan available to them.
We separate portfolio economics from regional prices
Part D costs can include the monthly premium, deductible, tier-specific copays or coinsurance and differences in what a prescription costs at different pharmacies. These amounts can vary across exact plans, so they require careful handling in a portfolio-level review.
MarketReview may use exact-plan pricing to understand how a plan family is constructed or to illustrate a documented feature. We do not take the premium or deductible from one region and publish it as though it were a national price for the carrier.
Instead, we examine the broader cost strategy where the evidence supports one. For example, a portfolio may include a plan family positioned around lower premiums, another with a different deductible structure or an option aimed at beneficiaries receiving Extra Help. Those distinctions can be useful at the portfolio level even though the actual dollar amounts still need to be confirmed locally.
A low premium does not automatically produce a stronger review. The deductible, drug tier, coinsurance, pharmacy choice and prescriptions used can have a larger effect on annual spending. Our editorial assessment considers that interaction rather than rewarding the cheapest advertised number.
Pharmacy access is evaluated as a cost issue as well as a convenience issue
Part D pharmacy networks can distinguish between preferred and standard in-network pharmacies, which means two participating pharmacies may produce different out-of-pocket costs for the same covered prescription.
For that reason, we look beyond broad claims about network size. We consider whether the portfolio makes its pharmacy arrangements understandable, whether preferred-pharmacy structures play a meaningful role in its plan design and whether members have practical tools for finding participating pharmacies.
Mail-order access can also be relevant, particularly for people taking stable maintenance medications. It is not automatically treated as an advantage. The value depends on pricing, prescription type and whether a beneficiary actually wants to use home delivery.
As with formulary information, the final pharmacy check belongs at the exact-plan level. A national carrier presence does not guarantee that a specific pharmacy has preferred status under every plan.
Multiple plan families are judged on whether the choice is useful
Some Part D portfolios contain several marketed plan families while others are centered on a smaller number of options. We do not award a stronger rating simply because a company offers more plans.
Additional plan families can be valuable when they create meaningful choices for different prescription or cost profiles. They can also create complexity when the differences are difficult to understand or when shoppers are likely to compare plans with very different purposes using premium alone.
Our review considers whether the portfolio has a coherent structure, whether the major plan-family differences are understandable and whether the available choices appear to serve distinct consumer needs. A simpler portfolio can score well when its design is clear and useful. A larger portfolio can score well when the additional choice adds genuine flexibility rather than duplication.
We consider the tools needed to use the coverage
A Part D plan can require interaction well after enrollment. Members may need to search for a drug, check a pharmacy, review claim information, request a coverage determination, understand a restriction or begin an exception or appeal.
Where reliable evidence is available, we consider whether the carrier provides accessible formularies, pharmacy directories, prescription-cost tools, coverage-rule information and member resources that support those tasks.
Digital polish is not a substitute for good prescription coverage. A sophisticated website does not offset an unfavorable formulary or poor cost fit. We therefore treat tools and usability as supporting considerations rather than allowing them to dominate the rating.
CMS quality data is evidence, not a substitute for our review
CMS publishes Medicare Part D Star Ratings using its own quality and performance measures. We use relevant CMS quality information as an independent source of contract-level evidence.
We do not rename a CMS Star Rating as a MarketReview Rating, convert it mechanically into our score or treat it as proof that the portfolio is suitable for every beneficiary. CMS is measuring defined aspects of contract performance. MarketReview is assessing the broader consumer-facing Part D portfolio and the trade-offs a shopper encounters when considering it.
This separation also prevents double counting. If CMS performance data informs our judgment about an area such as service or drug-plan performance, we do not need to invent another proprietary measure that merely restates the same evidence.
Our rating is editorial judgment, not a hidden weighted formula
MarketReview does not claim that Medicare Part D quality can be reduced to a secret mathematical formula in which every factor receives a fixed percentage weight.
Some evidence is objective. A portfolio has a defined number of plan families. A formulary lists particular restrictions. CMS publishes contract-level quality data. Official plan documents establish specific benefits and rules.
Other questions require editorial judgment. Is the portfolio meaningfully differentiated? Are important limitations easy to identify? Does its structure make sense for the consumers it appears designed to serve? Are cost-focused features useful enough to offset other restrictions? Does a strength apply broadly across the portfolio or only to one exact plan?
The importance of each factor depends on the evidence and the Part D portfolio being reviewed. Drug coverage, cost structure and practical access normally matter more than peripheral conveniences, but we do not manufacture numerical precision where the underlying evidence does not justify it.
The published MarketReview Rating represents our overall assessment of the defined portfolio subject for that plan year. The written review is essential because it explains the strengths, drawbacks and limitations behind the rating.
What can cause a Part D rating to change
A Part D portfolio can change substantially from one coverage year to the next. A carrier may add or remove plan families, alter formularies, revise premiums or deductibles, change pharmacy arrangements or operate under different market conditions. CMS quality information can also change as new Star Ratings are published.
We may reassess a rating when material portfolio evidence changes, when a new plan year begins, when reliable new information becomes available or when we identify an error that affects the previous conclusion.
A rating should not be treated as permanent. The plan-year component of the review subject matters because an assessment based on one year's Part D portfolio should not silently carry forward after the underlying product has materially changed.
What our Part D reviews cannot decide for you
A portfolio-level review cannot identify the cheapest or most suitable exact plan for every Medicare beneficiary. Prescription lists differ. Pharmacies differ. Eligibility for Extra Help differs. Regional premiums and benefit packages differ. Even two people in the same location may reach different conclusions because they take different drugs.
Use a MarketReview review to understand the company and decide whether its Part D portfolio deserves a place on your shortlist. Before enrolling, identify the exact plan available in your area and confirm its current premium, formulary, drug tiers, restrictions, pharmacy network and expected prescription costs using your own medications.
That final verification is not a limitation we try to hide with a broader rating. It is an essential part of comparing Medicare Part D plans responsibly.